From: Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma
All | KRAS wild-type | KRAS mutated | |||||
---|---|---|---|---|---|---|---|
n (events) | HR (95% CI) | n (events) | HR (95% CI) | n (events) | HR (95% CI) | Pinteraction | |
ER status | |||||||
All | |||||||
ER- | 118 (93) | 1.00 | 40 (27) | 1.00 | 34 (28) | 1.00 | 0.694 |
ER+ | 48 (39) | 0.97 (0.67–1.41) | 13 (10) | 1.14 (0.55–2.37) | 12 (11) | 0.93 (0.46–1.88) | 0.757a |
p | 0.865 | 0.721 | 0.841 | ||||
Women | |||||||
ER- | 49 (35) | 1.00 | 17 (10) | 1.00 | 14 (10) | 1.00 | 0.874 |
ER+ | 35 (26) | 1.05 (0.63–1.74) | 8 (5) | 1.09 (0.37–3.22) | 8 (7) | 1.35 (0.50–3.65) | 0.947a |
p | 0.864 | 0.870 | 0.548 | ||||
Men | |||||||
ER- | 69 (58) | 1.00 | 23 (17) | 1.00 | 20 (18) | 1.00 | 0.387 |
ER+ | 13 (13) | 1.12 (0.61–2.05) | 5 (5) | 1.30 (0.47–3.59) | 4 (4) | 0.63 (0.21–1.92) | 0.516a |
p | 0.723 | 0.613 | 0.420 | ||||
PR status | |||||||
All | |||||||
PR- | 111 (86) | 1.00 | 38 (24) | 1.00 | 29 (26) | 1.00 | 0.026 |
PR+ | 49 (43) | 1.25 (0.87–1.81) | 12 (11) | 1.94 (0.94–3.98) | 17 (14) | 0.66 (0.34–1.27) | 0.037a |
p | 0.234 | 0.071 | 0.216 | ||||
Women | |||||||
PR- | 52 (36) | 1.00 | 18 (9) | 1.00 | 12 (11) | 1.00 | 0.002 |
PR+ | 28 (24) | 1.35 (0.80–2.27) | 6 (6) | 2.85 (1.01–8.09) | 9 (6) | 0.030 (0.11–0.85) | 0.004a |
p | 0.257 | 0.048 | 0.024b | ||||
Men | |||||||
PR- | 59 (50) | 1.00 | 20 (15) | 1.00 | 17 (15) | 1.00 | 0.678 |
PR+ | 21 (19) | 1.23 (0.72–2.09) | 6 (5) | 1.32 (0.47–3.70) | 8 (8) | 1.70 (0.71–4.07) | 0.785a |
p | 0.452 | 0.592 | 0.234 |